We spoke to Professor Hugh Calkins (Johns Hopkins Hospital, Baltimore, MD, USA) about the STOP Persistent AF Clinical Trial (NCT03012841).
Questions:
- Could you tell us a little about the aims and design of the STOP Persistent AF clinical trial? (0.13)
- What were the findings of the study? (0.43)
- What are their implications for clinical practice? (2.19)
Speaker disclosures: Professor Hugh Calkins is a consultant and/or has received honoraria from Atricure, Biosense Webster, Abbott, Medtronic and Ablacon.
Commissioned, edited and funded by Touch Medical Media.
Filmed during a remote video call with Professor Hugh Calkins as a highlight of the AF Symposium, January 2021.
